Organogenesis Holdings Reports 57% Revenue Decline and $99.3 Million Net Loss

Organogenesis Holdings Inc. reported significant financial challenges in its quarterly filing for the period ending June 30, 2026. The company recorded total revenue of $43.8 million, a decline of 57% from $101 million in the same period last year. This drop was primarily driven by a 61% decrease in net product revenue from its Advanced Wound Care segment, which fell to $36.1 million from $92.7 million. The Surgical & Sports Medicine segment also saw a decline, with revenue decreasing by 18% to $6.7 million. The company’s net loss for the quarter was $99.3 million, compared to a loss of $12.2 million in the prior year, reflecting a substantial increase in operational challenges.

In terms of operational changes, Organogenesis has undertaken a restructuring plan that included a workforce reduction of approximately 18%, or 138 employees, in the second quarter of 2026. This restructuring is part of a broader strategy to enhance productivity and profitability amid declining revenues. The company also suspended manufacturing of its Dermagraft product, which is expected to transition to a new facility in Smithfield, Rhode Island, although the timeline for this transition remains uncertain due to market conditions.

The company’s cash position has also deteriorated, with cash and cash equivalents decreasing to $46.1 million from $93.7 million at the end of 2025. Accounts receivable also saw a significant reduction, dropping to $100.9 million from $217.5 million, indicating challenges in cash collection and sales. The total liabilities decreased to $118.3 million from $164.8 million, largely due to a reduction in current liabilities. However, the company’s accumulated deficit has grown to $152.5 million, up from $3.1 million at the end of the previous fiscal year.

Looking ahead, Organogenesis faces a challenging market environment, particularly due to changes in Medicare reimbursement policies that have led to clinician confusion and disruptions in product utilization. The company has indicated that it will prioritize certain products in its portfolio in response to these changes. Additionally, the company has initiated a rolling Biologics License Application (BLA) submission for its ReNu product, which was accepted for review by the FDA, with a target action date set for April 2027. Despite these efforts, the outlook remains uncertain as the company navigates significant operational and market challenges.